Sort   by:  
 Page size 
TranscriptomicsHCT116 cells treated with the p97 inhibitior CB-5083
The goal of this study was to analyze differential gene expression 8 hr after treatment of CB-5083, a small molecule inhibitor of p97 (VCP), in HCT116 cells grown in culture. DMSO treated cells were compared to cells treated with 1uM CB-5083 after 8 hr.
ORGANISM(S): Homo sapiens 
2015-11-09 | E-GEOD-73588 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human ovarian cancer cell line OVSAHO parental and CB-5083-resistant cells
The goal of this experiment is to identify differentially expressed genes between parental OVSAHO cells and CB-5083-resistant OVSAHO cells. Each group is treated with 5 microM CB-5083 for 6 hours and total RNA was extracted with Trizol. RNA sequencing library was performed using Illumina RNA library...
ORGANISM(S): Homo sapiens 
2018-11-02 | E-MTAB-7328 | biostudies-arrayexpress
ProteomicsDifferential Impact of p97 Inhibitor CB-5083 on Protein Dynamics in Nucleus, Cytoplasm, and Membrane Compartments
Human p97/VCP is a vital AAA ATPase (ATPase associated with diverse cellular activity) plays critical roles in autophagy, endosomal trafficking, and the ubiquitin-proteasome system. Mutations in p97 cause inclusion body myopathy associated with paget’s disease of bone and frontotemporal dementia. P9...
ORGANISM(S): Homo sapiens (Human) 
2025-05-07 | PXD056029 | Pride
P97 vcp P97 inhibitor  mass spectrometry. Cb-5083 
TranscriptomicsRNA-seq of MOLM-13 acute myeloid leukemia cell line treated with single and combination 5-Azacytidine and CB-5083
MOLM-13 acute myeloid leukemia cells were treated with 7 µM 5-Azacytidine (Cayman Chemical 11164), or 450 nM CB-5083 (Cayman Chemical 19311), or in combination, or 0.1% DMSO as control. Treatments were conducted for 48 hours.
ORGANISM(S): Homo sapiens 
2023-04-22 | E-MTAB-12848 | biostudies-arrayexpress
TranscriptomicsGene expression profile of multiple myeloma cell lines treated with CB-5083
The goal was to determine the gene expression differences between CB-5083 and Bortezomib treated multiple myeloma cell lines Inhibition of the AAA ATPase, p97, was recently shown to be a novel method for targeting the ubiquitin proteasome system (UPS) and CB-5083, a first in class inhibitor of p97, ...
ORGANISM(S): Homo sapiens 
2017-10-26 | GSE101923 | GEO
GenomicsRNA-seq of human ovarian cancer cell line OVSAHO parental and CB-5083-resistant cells
RNA-seq of human ovarian cancer cell line OVSAHO parental and CB-5083-resistant cells
PRJEB29293 | ENA
TranscriptomicsHCT116 cells treated with the p97 inhibitior CB-5083
The goal of this study was to analyze differential gene expression 8 hr after treatment of CB-5083, a small molecule inhibitor of p97 (VCP), in HCT116 cells grown in culture.
ORGANISM(S): Homo sapiens 
2015-11-09 | GSE73588 | GEO
UnknownThrombospondin-1 counteracts the p97 inhibitor CB-5083 in colon carcinoma cells.
Not available
S-EPMC7469669 | biostudies-literature
UnknownStructural Basis of p97 Inhibition by the Site-Selective Anticancer Compound CB-5083.
Not available
S-EPMC6355941 | biostudies-literature
UnknownA p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6.
Not available
S-EPMC8456514 | biostudies-literature
Sort   by:  
 Page size